ClinicalTrials.gg
CompletedNCT01406470Updated Jan 10, 2014

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

A Phase 3 interventional study of Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ in Immunologic Deficiency Syndrome, sponsored by Green Cross Corporation. Completed at 11 sites in 2 countries. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-01-10.

Sponsored by Green Cross Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
2 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Immunologic Deficiency Syndromes with a site in United States — 27 open to participants now, 34 under way, none of them phase 3. Immunologic Deficiency Syndromes · United States.

Enrollment
24th of 77
45 · median 28
Started
2011
with 4 others
Phase 3
8 of 127
none open now
Registered
66th of 127
by date

Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, this one is the 24th largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2011, is one of 8 in phase 3, and was the 66th registered.

Immunologic Deficiency Syndromes

204 studies on the registry are indexed under Immunologic Deficiency Syndromes; 50 are open to participants now.

Browse Immunologic Deficiency Syndromes studies →

Open to participants now

27 of the 127 studies in Immunologic Deficiency Syndromes with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger; 30 take children under 18; 10 take healthy volunteers.

This study: 2 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Immunologic Deficiency Syndromes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.

Read the detailed description

This is an open-label, single-arm, historically controlled, prospective, multicenter phase III study to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.

Subject will be infused every 21 to 28 days according to their previous IVIG treatment schedule. Subjects treated every 28 days will receive 13 study IVIG infusions. Subject treated every 21 days will receive 17 study IVIG infusions.

Duration of treatment:The total duration of treatment is 12 months.

03

Conditions studied

  • Immunologic Deficiency Syndrome

Keywords

  • IGIV
  • Primary Immune Deficiency
  • Immunoglobulin G
04

Who can participate

Ages eligible
2 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a confirmed clinical diagnosis of a Primary Immunodeficiency Disease as defined by IUIS (International Union of Immunological Societies) and require treatment with IVIG. Documented agammaglobulinemia or hypogammaglobulinemia (preferably with documented antibody deficiency).
  • Male or female, ages 2 to 70 years.
  • The subject has received 300-900 mg/kg of a licensed IGIV therapy at 21 or 28 day intervals for at least 3 months prior to this study.
  • At least 2 documented IgG trough levels of ≥ 5 g/L are obtained at two infusion cycles (21 or 28 days) within 12 months prior to study enrollment.
  • Subject is willing to comply with all requirements of the protocol.
  • Females of with a negative urine pregnancy test and who agree to employ adequate measures during the study.
  • Subject, parent or guardian has signed the form and a child assent form if appropriate. Pediatric subjects are defined as 2-17 years of age at study entry and will require assent forms as appropriate per study documentation and regulations of the local jurisdiction.
  • Authorization to access personal health information.
  • Subjects currently participating in a clinical trial with another experimental IVIG may be enrolled if they have received stable IVIG therapy for at least 3 infusion cycles prior to receiving IVIG-SN™ and all inclusion and exclusion criteria are satisfied. Other IVIGs will be prohibited between the first infusion of IVIG-SN™ and Follow Up Visit 1.
  • Subjects currently participating in a trial of SCIG can be enrolled if they are switched to IVIG for three infusion cycles (21 or 28 days) prior to enrollment in this study.

Exclusion criteria

Exclusion Criteria:

  • Subject has secondary immunodeficiency.
  • Subject was newly diagnosed and has not been treated with immunoglobulin or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency.
  • Subject has a history of repeated reactions or to IVIG or other injectable forms of IgG.
  • Subject has a history of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism or , or myocardial infarction, as defined by at least 1 event in subject's lifetime.
  • Subject has IgA deficiency and is known to have antibodies to IgA.
  • Subject has received blood products other than human albumin or human immunoglobulin within 12 months prior to enrollment.
  • Subject has significant protein losing enteropathy, nephrotic syndrome or lymphangiectasia.
  • Subject has an acute infection as documented by culture or diagnostic imaging and/or a body temperature exceeding 38.5 °C (101.3 °F) within 7 days prior to screening
  • Subject has a known history or is positive at enrollment for (HIV) type 1/2 by NAT or virus (HBsAg and NAT) or virus (by NAT), or hepatitis A virus (by NAT).
  • Subject has levels of (ALT) or aspartate aminotransferase (AST) > 2.5 times of the for the laboratory designated for the study.
  • Subject is using an implanted venous access device
  • Subject has profound anemia or persistent severe neutropenia (≤ 1000 neutrophils per mm3).
  • Subject has a severe chronic condition such as renal failure (creatinine concentration > 2.0 times the upper limit of normal) with proteinuria, congestive heart failure ( III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g. atrial fibrillation), unstable or advanced ischemic heart disease, or hyperviscosity, or any other condition that the investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
  • Subject has a history of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to enrollment.
  • Subject has history of epilepsy or multiple episodes of migraine not completely controlled by medication.
  • Subject is receiving the following medication:

    • (oral or parenteral daily dose of ≥ 0.15 mg/kg/day of prednisone or equivalent).
    • Other drugs or chemotherapy.
  • Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
  • Subject has participated in another clinical study within 3 weeks prior to study enrollment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    IVIG-SN™

    Immune Globulin Intravenous (Human) 5% Liquid

    Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™

Interventions

  • IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.

    Also known as: IGIV, Immune Globulin Intravenous (Human) 5% Liquid

06

What researchers measure

Primary outcomes

  1. Incidence of acute serious bacterial infections

    Time frame: one year

  2. Overall incidence of adverse events that occur during or within 1 hour, 24 hours and 72 hours following an infusion of test product

    Time frame: Within 72 hours after treatment with IVIG-SN

  3. The Pharmacokinetic (PK) Area under the curve (AUC0-t, AUC0-inf) of Immunoglobulin G (IgG).

    Time frame: After 5th infusion

  4. The Pharmacokinetic (PK) Maximum concentration (Cmax) of Immunoglobulin G (IgG).

    Time frame: After 5th infusion

Secondary outcomes

  1. The number of days missed work/school/kindergarten/day care or unable to perform normal daily activities due to infection.

    Time frame: one year

  2. Days of unscheduled physician visits and hospitalizations due to infection

    Time frame: One year

  3. Number of days on therapeutic antibiotics

    Time frame: One year

  4. The incidence of infections other than acute serious bacterial infections

    Time frame: One year

  5. Annual rate of fever episodes per patient

    Time frame: One year

  6. All adverse events regardless of causality assessment by investigator

    Time frame: One year

  7. The proportion and number of IGIV infusions for which the infusion rate was decreased due to adverse events

    Time frame: One year

  8. The proportion of adverse events considered by the investigator to be product related

    Time frame: One year

  9. To monitor viral safety (freedom from transmission of blood borne virus diseases)

    Time frame: One year

  10. Descriptive analyses of PK parameters for specific antibodies (anti-Hemophilus influenza type b, anti-Streptococcus pneumonia serotypes, anti-Tetanus toxoid, anti-cytomegalovirus (CMV), anti-measles) will be performed.

    Time frame: One year

07

Study locations

11 sites
  • University of Alabama Hospital
    Birmingham, Alabama 35233, United States
  • Allergy Associates of the Palm Beaches
    North Palm Beach, Florida 33408, United States
  • Rush University Medical Center
    Chicago, Illinois 33408, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Optimed Research, LTD
    Columbus, Ohio 43235, United States
  • Dallas Allergy Immunology
    Dallas, Texas 75230, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Children's Hospital of Richmond
    Richmond, Virginia 23219, United States
  • Bellingham Asthma, Allergy & Immunology Clinic
    Bellingham, Washington 98225, United States
  • Gordon Sussman Clinical Research Inc.
    Toronto, Ontario M4V1R2, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G1X8, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2011
First posted
Aug 1, 2011
Start
Sep 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Jan 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01406470
Collaborators
Atlantic Research Group
Responsible party
Sponsor
First posted
Aug 1, 2011
Start date
Sep 2011
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Jan 10, 2014

Study contacts

Chaim Roifman, MD
study chair · The Hospital for Sick Children

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion